Motley Fool Money JP Morgan Healthcare Conference Highlights
Jan 20, 2024
Karl Thiel, a biotech analyst at Motley Fool, shares fascinating insights from the JPMorgan Healthcare Conference. He discusses the spotlight on weight loss drugs and their impact on health trends. Thiel delves into Biogen's efforts at developing an Alzheimer's treatment and the innovative role of NVIDIA in drug development. He also touches on Moderna's evolving vaccine strategy and highlights new technologies in diabetes management, emphasizing the need for robust trial outcomes to boost investor confidence.
AI Snips
Chapters
Books
Transcript
Episode notes
GLP-1 Drug History
- Eli Lilly's first GLP-1 drug, Bieta, launched in 2005 after they acquired Amylin Pharmaceuticals.
- Ozempic, a more recent GLP-1 drug, has been available since 2017, but gained popularity through word of mouth and social media starting in 2021.
GLP-1 Drug Competition
- Many companies are developing GLP-1 drugs, making it difficult to pick winners.
- Larger companies like Lilly and Novo Nordisk have manufacturing advantages.
Amgen's Dual-Action Drug
- Amgen's drug, Meritide, offers a dual mechanism of action.
- This might help address concerns about long-term GLP-1 use and muscle loss.
